Digital Controlling AI hallucinations: Building evidence-based trust... When it comes to GenAI, industry must demand evidence-grounded systems that prioritise verifiable clinical data and rigorous human oversight.
Digital Regulators open the AI floodgates in life sciences In 2026, biopharma will move from proving AI works to proving it can be trusted at scale.
Sales & Marketing Sponsored Beyond the grid: Rethinking tracking studies for pharma’s ne... As the healthcare landscape continues to evolve rapidly, the tools used to understand it must keep pace.
Digital Sponsored What does it mean to have an AI-first mindset in pharma? The importance of AI in pharma and life sciences cannot be overstated.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
R&D Post-hype, pre-value: The real AI-pharma shift starts now The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.